A phase 2 efficacy and safety study of SU011248 [sunitinib] administered in a continuous daily regimen in patients with advanced gastrointestinal stromal tumor
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Sunitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2009 Results have been reported in the European Journal of Cancer.
- 01 Sep 2008 Results presented at the European Society for Medical Oncology.
- 10 Jun 2008 The expected completion date for this trial is now 1 Jun 2008.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History